Last reviewed · How we verify
Paclitaxel + Trastuzumab
Paclitaxel works by inhibiting microtubule dynamics, thereby inducing cell cycle arrest and apoptosis in rapidly dividing cancer cells. Trastuzumab targets the HER2/neu receptor, which is overexpressed in certain breast cancer cells, and triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Paclitaxel works by inhibiting microtubule dynamics, thereby inducing cell cycle arrest and apoptosis in rapidly dividing cancer cells. Trastuzumab targets the HER2/neu receptor, which is overexpressed in certain breast cancer cells, and triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Used for Adjuvant treatment of node-positive breast cancer, First-line treatment of HER2-positive metastatic breast cancer.
At a glance
| Generic name | Paclitaxel + Trastuzumab |
|---|---|
| Sponsor | Institut de cancérologie Strasbourg Europe |
| Drug class | Taxane + monoclonal antibody |
| Target | Microtubules + HER2/neu receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel's mechanism of action involves the stabilization of microtubules, preventing their disassembly and thereby inhibiting cell division. This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Trastuzumab, on the other hand, is a monoclonal antibody that binds to the HER2/neu receptor, which is overexpressed in certain breast cancer cells. This binding triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, ultimately leading to the death of cancer cells.
Approved indications
- Adjuvant treatment of node-positive breast cancer
- First-line treatment of HER2-positive metastatic breast cancer
Common side effects
- Neutropenia
- Fatigue
- Anemia
- Diarrhea
- Nausea
Key clinical trials
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (PHASE3)
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) (PHASE3)
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
- Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery (PHASE2)
- A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (PHASE1)
- The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis (PHASE2)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paclitaxel + Trastuzumab CI brief — competitive landscape report
- Paclitaxel + Trastuzumab updates RSS · CI watch RSS
- Institut de cancérologie Strasbourg Europe portfolio CI